Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/201750
Type: Artigo de periódico
Title: The Real-life Experience With Cardiovascular Complications In The First Dose Of Fingolimod For Multiple Sclerosis.
Author: Fragoso, Yara Dadalti
Arruda, Christian Cardoso
Arruda, Walter Oleschko
Brooks, Joseph Bruno Bidin
Damasceno, Alfredo
Damasceno, Carlos Augusto de Albuquerque
Finkelsztejn, Alessandro
Finkelsztejn, Juliana
Gama, Paulo Diniz da
Giacomo, Maria Cristina Brandão
Gomes, Sidney
Goncalves, Marcus Vinicius Magno
Matta, Andre Palma da Cunha
de Morais, Marilia Manprim
Oliveira, Enedina Maria Lobato de
Ribeiro, Yuna
Sato, Henry Koiti
Tauil, Carlos Bernardo
Abstract: Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.
Subject: Adult
Aged
Bradycardia
Cardiovascular Diseases
Female
Heart Rate
Humans
Immunosuppressive Agents
Male
Middle Aged
Multiple Sclerosis
Propylene Glycols
Sphingosine
Time Factors
Young Adult
Rights: aberto
Identifier DOI: 
Address: http://www.ncbi.nlm.nih.gov/pubmed/25252236
Date Issue: 2014
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_25252236.pdf99.97 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.